中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 40 Issue 3
Mar.  2024
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2024  >  40(3): 594-599

Role of Akkermansia muciniphila in nonalcoholic fatty liver disease

DOI: 10.12449/JCH240326
  • 1.

    Department of Gastroenterology，The 940th Hospital of Joint Logistic Support Force of PLA，Lanzhou 730050，China

  • 2.

    The First Clinical Medical College of Gansu University of Chinese Medicine，Lanzhou 730000，China

Research funding:

Gansu Province Clinical Research Center for Noninfectious Liver Diseases (21JR7RA017);

Liver Disease Clinical Medicine Research Center of the 940th Hospital of Joint Service Support Force (2021yxky079);

Scientific Research Management Project of Gansu Province Health Commission (GSWSKY2021-047)

More Information
  • Corresponding author: YU Xiaohui， yuxiaohui528@126.com （ORCID： 0000-0002-8633-3281）
  • Received Date: 2023-08-08
  • Accepted Date: 2023-08-30
  • Published Date: 2024-03-20
    Abstract
  • Nonalcoholic fatty liver disease （NAFLD） has become the most common chronic liver disease in the world， and it is also one of the main causes of liver cirrhosis and hepatocellular carcinoma， so it is particularly important to curb the development and progression of NAFLD in a timely manner. However， due to its complex pathogeneses， there are currently no effective methods for radical treatment. As a new generation of probiotics， Akkermansia muciniphila （Akk bacteria） can improve metabolic disorders of the body， and more and more studies have shown that Akk bacteria have a potential therapeutic effect on metabolic diseases， especially NAFLD. Therefore， this article briefly reviews the mechanism of action of Akk bacteria in NAFLD， in order to provide new ideas for improving the treatment of NAFLD and creating new therapies.

     

    • FullText(HTML)
  • loading
    • References(52)
  • [1]
    RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
    [2]
    WU CM, ZHANG CY, XU HL, et al. Epidemiological research and diagnosis of nonalcoholic fatty liver disease in China[J]. China Med Herald, 2023, 20( 11): 158- 161. DOI: 10.20047/j.issn1673-7210.2023.11.36.

    吴车敏, 张从玉, 徐慧丽, 等. 我国非酒精性脂肪性肝病的流行病学研究和诊断现状分析[J]. 中国医药导报, 2023, 20( 11): 158- 161. DOI: 10.20047/j.issn1673-7210.2023.11.36.
    [3]
    JIN R, WANG XX, LIU F, et al. Research advances in pharmacotherapy for nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38( 7): 1634- 1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.

    靳睿, 王晓晓, 刘峰, 等. 非酒精性脂肪性肝病的药物治疗进展[J]. 临床肝胆病杂志, 2022, 38( 7): 1634- 1640. DOI: 10.3969/j.issn.1001-5256.2022.07.033.
    [4]
    ZHAO Q, YU J, HAO Y, et al. Akkermansiamuciniphila plays critical roles in host health[J]. Crit Rev Microbiol, 2023, 49( 1): 82- 100. DOI: 10.1080/1040841X.2022.2037506.
    [5]
    SHEN K, SINGH AD, MODARESI ESFEH J, et al. Therapies for non-alcoholic fatty liver disease: A 2022 update[J]. World J Hepatol, 2022, 14( 9): 1718- 1729. DOI: 10.4254/wjh.v14.i9.1718.
    [6]
    LI YQ, TANG WJ, ZHOU YJ. Role of intestinal microbiota and metabolites in the development, progression, and treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2023, 39( 8): 1805- 1810. DOI: 10.3969/j.issn.1001-5256.2023.08.006.

    李永强, 唐文娟, 周永健. 肠道菌群及其代谢产物在非酒精性脂肪性肝病发生发展及治疗中的作用[J]. 临床肝胆病杂志, 2023, 39( 8): 1805- 1810. DOI: 10.3969/j.issn.1001-5256.2023.08.006.
    [7]
    BELKAID Y, HARRISON OJ. Homeostatic immunity and the microbiota[J]. Immunity, 2017, 46( 4): 562- 576. DOI: 10.1016/j.immuni.2017.04.008.
    [8]
    CANI PD, DEPOMMIER C, DERRIEN M, et al. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms[J]. Nat Rev Gastroenterol Hepatol, 2022, 19( 10): 625- 637. DOI: 10.1038/s41575-022-00631-9.
    [9]
    SI J, KANG H, YOU HJ, et al. Revisiting the role of Akkermansia muciniphila as a therapeutic bacterium[J]. Gut Microbes, 2022, 14( 1): 2078619. DOI: 10.1080/19490976.2022.2078619.
    [10]
    BAE M, CASSILLY CD, LIU X, et al. Akkermansia muciniphilaphospholipid induces homeostatic immune responses[J]. Nature, 2022, 608( 7921): 168- 173. DOI: 10.1038/s41586-022-04985-7.
    [11]
    KESHAVARZ AZIZI RAFTAR S, ASHRAFIAN F, YADEGAR A, et al. The protective effects of live and pasteurized akkermansiamuciniphila and its extracellular vesicles against HFD/CCl4-induced liver injury[J]. Microbiol Spectr, 2021, 9( 2): e0048421. DOI: 10.1128/Spectrum.00484-21.
    [12]
    KIM S, SHIN YC, KIM TY, et al. Mucin degrader Akkermansiamuciniphila accelerates intestinal stem cell-mediated epithelial development[J]. Gut Microbes, 2021, 13( 1): 1- 20. DOI: 10.1080/19490976.2021.1892441.
    [13]
    QU S, FAN L, QI Y, et al. Akkermansiamuciniphila Alleviates Dextran Sulfate Sodium(DSS)-induced acute colitis by NLRP3 activation[J]. Microbiol Spectr, 2021, 9( 2): e0073021. DOI: 10.1128/Spectrum.00730-21.
    [14]
    REUNANEN J, KAINULAINEN V, HUUSKONEN L, et al. Akkermansia muciniphila adheres to enterocytes and strengthens the integrity of the epithelial cell layer[J]. Appl Environ Microbiol, 2015, 81( 11): 3655- 3662. DOI: 10.1128/AEM.04050-14.
    [15]
    LOPETUSO LR, QUAGLIARIELLO A, SCHIAVONI M, et al. Towards a disease-associated common trait of gut microbiota dysbiosis: The pivotal role of Akkermansia muciniphila[J]. Dig Liver Dis, 2020, 52( 9): 1002- 1010. DOI: 10.1016/j.dld.2020.05.020.
    [16]
    SUN XW, HE JH, JIANG XZ, et al. Probiotics A. muciniphila improving diarrhea induced by ETEC in mice[J]. Acta Univ Med Nanjing(Natural Science Edition), 2023, 43( 1): 27- 33. DOI: 10.7655/NYDXBNS20230104.

    孙学伟, 何君花, 姜新泽, 等. 益生菌A. muciniphila改善大肠杆菌诱导的小鼠腹泻[J]. 南京医科大学学报(自然科学版), 2023, 43( 1): 27- 33. DOI: 10.7655/NYDXBNS20230104.
    [17]
    ŠEŠELJA K, BAZINA I, VRECL M, et al. TFF3 deficiency protects against hepatic fat accumulation after prolonged high-fat diet[J]. Life(Basel), 2022, 12( 8): 1288. DOI: 10.3390/life12081288.
    [18]
    BARCENA C, VALDES-MAS R, MAYORAL P, et al. Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice[J]. Nat Med, 2019, 25( 8): 1234- 1242. DOI: 10.1038/s41591-019-0504-5.
    [19]
    van der LUGT B, van BEEK AA, AALVINK S, et al. Akkermansia muciniphila ameliorates the age-related decline in colonic mucus thickness and attenuates immune activation in accelerated aging Ercc1-/Δ7 mice[J]. Immun Ageing, 2019, 16: 6. DOI: 10.1186/s12979-019-0145-z.
    [20]
    GRANDER C, GRABHERR F, SPADONI I, et al. The role of gut vascular barrier in experimental alcoholic liver disease and A. muciniphila supplementation[J]. Gut Microbes, 2020, 12( 1): 1851986. DOI: 10.1080/19490976.2020.1851986.
    [21]
    BI M, LIU C, WANG Y, et al. Therapeutic prospect of new probiotics in neurodegenerative diseases[J]. Microorganisms, 2023, 11( 6): 1527. DOI: 10.3390/microorganisms11061527.
    [22]
    OU Z, DENG L, LU Z, et al. Protective effects of Akkermansiamuciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer’s disease[J]. Nutr Diabetes, 2020, 10( 1): 12. DOI: 10.1016/j.jep.2023.116505.
    [23]
    LIU J, LIU H, LIU H, et al. Live and pasteurized Akkermansia muciniphila decrease susceptibility to Salmonella Typhimurium infection in mice[J]. J Adv Res, 2023, 52: 89- 102. DOI: 10.1016/j.jare.2023.03.008.
    [24]
    LI J, YANG G, ZHANG Q, et al. Function of Akkermansia muciniphila in type 2 diabetes and related diseases[J]. Front Microbiol, 2023, 14: 1172400. DOI: 10.3389/fmicb.2023.1172400.
    [25]
    HOYLES L, FERNÁNDEZ-REAL JM, FEDERICI M, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women[J]. Nat Med, 2018, 24( 7): 1070- 1080. DOI: 10.1038/s41591-018-0061-3.
    [26]
    TSAI HJ, TSAI YC, HUNG WW, et al. Gut microbiota and non-alcoholic fatty liver disease severity in type 2 diabetes patients[J]. J Pers Med, 2021, 11( 3). DOI: 10.3390/jpm11030238.
    [27]
    ÖZKUL C, YALıNAY M, KARAKAN T, et al. Determination of certain bacterial groups in gut microbiota and endotoxin levels in patients with nonalcoholic steatohepatitis[J]. Turk J Gastroenterol, 2017, 28( 5): 361- 369. DOI: 10.5152/tjg.2017.17033.
    [28]
    LIANG T, LI D, ZUNONG J, et al. Interplay of lymphocytes with the intestinal microbiota in children with nonalcoholic fatty liver disease[J]. Nutrients, 2022, 14( 21): 4641. DOI: 10.3390/nu14214641.
    [29]
    PAN X, KAMINGA AC, LIU A, et al. Gut microbiota, glucose, lipid, and water-electrolyte metabolism in children with nonalcoholic fatty liver disease[J]. Front Cell Infect Microbiol, 2021, 11: 683743. DOI: 10.3389/fcimb.2021.683743.
    [30]
    KIM S, LEE Y, KIM Y, et al. Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis[J]. Appl Environ Microbiol, 2020, 86( 7): e03004-19. DOI: 10.1128/AEM.03004-19.
    [31]
    SHI Z, LEI H, CHEN G, et al. Impaired intestinal Akkermansia muciniphila and Aryl hydrocarbon receptor ligands contribute to nonalcoholic fatty liver disease in mice[J]. mSystems, 2021, 6( 1): e00985-20. DOI: 10.1128/mSystems.00985-20.
    [32]
    YE JZ, LI YT, WU WR, et al. Dynamic alterations in the gut microbiota and metabolome during the development of methionine-choline-deficient diet-induced nonalcoholic steatohepatitis[J]. World J Gastroenterol, 2018, 24( 23): 2468- 2481. DOI: 10.3748/wjg.v24.i23.2468.
    [33]
    CHOPYK DM, GRAKOUI A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders[J]. Gastroenterology, 2020, 159( 3): 849- 863. DOI: 10.1053/j.gastro.2020.04.077.
    [34]
    CARPINO G, DEL BEN M, PASTORI D, et al. Increased liver localization of lipopolysaccharides in human and experimental NAFLD[J]. Hepatology, 2020, 72( 2): 470- 485. DOI: 10.1002/hep.31056.
    [35]
    ZHAO S, LIU W, WANG J, et al. Akkermansia muciniphila improves metabolic profiles by reducing inflammation in chow diet-fed mice[J]. J Mol Endocrinol, 2017, 58( 1): 1- 14. DOI: 10.1530/JME-16-0054.
    [36]
    WU W, LV L, SHI D, et al. Protective effect of Akkermansia muciniphila against immune-mediated liver injury in a mouse model[J]. Front Microbiol, 2017, 8: 1804. DOI: 10.3389/fmicb.2017.01804.
    [37]
    CLIFFORD BL, SEDGEMAN LR, WILLIAMS KJ, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption[J]. Cell Metab, 2021, 33( 8): 1671- 1684. e 4. DOI: 10.1016/j.cmet.2021.06.012.
    [38]
    YAN N, YAN T, XIA Y, et al. The pathophysiological function of non-gastrointestinal farnesoid X receptor[J]. Pharmacol Ther, 2021, 226: 107867. DOI: 10.1016/j.pharmthera.2021.107867.
    [39]
    NIAN F, WU L, XIA Q, et al. Akkermansia muciniphila and bifidobacterium bifidum prevent NAFLD by regulating FXR expression and gut microbiota[J]. J Clin Transl Hepatol, 2023, 11( 4): 763- 776. DOI: 10.14218/JCTH.2022.00415.
    [40]
    LENG W, LIU Y, SHI H, et al. Aspartate alleviates liver injury and regulates mRNA expressions of TLR4 and NOD signaling-related genes in weaned pigs after lipopolysaccharide challenge[J]. J Nutr Biochem, 2014, 25( 6): 592- 599. DOI: 10.1016/j.jnutbio.2014.01.010.
    [41]
    RAO Y, KUANG Z, LI C, et al. Gut Akkermansia muciniphila ameliorates metabolic dysfunction-associated fatty liver disease by regulating the metabolism of L-aspartate via gut-liver axis[J]. Gut Microbes, 2021, 13( 1): 1- 19. DOI: 10.1080/19490976.2021.1927633.
    [42]
    KAZANKOV K, JØRGENSEN S, THOMSEN KL, et al. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Nat Rev Gastroenterol Hepatol, 2019, 16( 3): 145- 159. DOI: 10.1038/s41575-018-0082-x.
    [43]
    HAN Y, LING Q, WU L, et al. Akkermansia muciniphila inhibits nonalcoholic steatohepatitis by orchestrating TLR2-activated γδT17 cell and macrophage polarization[J]. Gut Microbes, 2023, 15( 1): 2221485. DOI: 10.1080/19490976.2023.2221485.
    [44]
    NEGI CK, BABICA P, BAJARD L, et al. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease[J]. Metabolism, 2022, 126: 154925. DOI: 10.1016/j.metabol.2021.154925.
    [45]
    MOREIRA GV, AZEVEDO FF, RIBEIRO LM, et al. Liraglutide modulates gut microbiota and reduces NAFLD in obese mice[J]. J Nutr Biochem, 2018, 62: 143- 154. DOI: 10.1016/j.jnutbio.2018.07.009.
    [46]
    DU J, ZHANG P, LUO J, et al. Dietary betaine prevents obesity through gut microbiota-drived microRNA-378a family[J]. Gut Microbes, 2021, 13( 1): 1- 19. DOI: 10.1080/19490976.2020.1862612.
    [47]
    ZHANG Y, YANG L, ZHAO N, et al. Soluble polysaccharide derived from Laminaria japonica attenuates obesity-related nonalcoholic fatty liver disease associated with gut microbiota regulation[J]. Mar Drugs, 2021, 19( 12): 699. DOI: 10.3390/md19120699.
    [48]
    PÉREZ-MONTER C, ÁLVAREZ-ARCE A, NUÑO-LAMBARRI N, et al. Inulin improves diet-induced hepatic steatosis and increases intestinal akkermansia genus level[J]. Int J Mol Sci, 2022, 23( 2): 991. DOI: 10.3390/ijms23020991.
    [49]
    ZHANG WJ, LI T. Akkermansia muciniphila suppresses non-alcoholic steatohepatitis-associated liver cancer in mice by recovering intestinal barrier function[J]. Cancer Res Prevent Treat, 2023, 50( 5): 463- 469. DOI: 10.3971/j.issn.1000-8578.2023.22.1259.

    张武剑, 李桃. 嗜蛋白阿克曼菌通过保护肠道屏障功能抑制小鼠非酒精性脂肪性肝炎相关肝癌[J]. 肿瘤防治研究, 2023, 50( 5): 463- 469. DOI: 10.3971/j.issn.1000-8578.2023.22.1259.
    [50]
    HIGARZA SG, ARBOLEYA S, ARIAS JL, et al. Akkermansia muciniphila and environmental enrichment reverse cognitive impairment associated with high-fat high-cholesterol consumption in rats[J]. Gut Microbes, 2021, 13( 1): 1- 20. DOI: 10.1080/19490976.2021.1880240.
    [51]
    AGUZZI A, BARRES BA, BENNETT ML. Microglia: scapegoat, saboteur, or something else?[J]. Science, 2013, 339( 6116): 156- 161. DOI: 10.1126/science.1227901.
    [52]
    YANG Y, ZHONG Z, WANG B, et al. Early-life high-fat diet-induced obesity programs hippocampal development and cognitive functions via regulation of gut commensal Akkermansia muciniphila[J]. Neuropsychopharmacology, 2019, 44( 12): 2054- 2064. DOI: 10.1038/s41386-019-0437-1.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (442) PDF downloads(64) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return